Celgene Corporation (CELG)

CELG (NASDAQ:Drugs)
$123.64
pos +0.20
+0.16%
Today's Range: 120.55 - 124.97 | CELG Avg Daily Volume: 3,210,400
Last Update: 05/23/13 - 4:00 PM EDT
Volume: 2,366,490
YTD Performance: 57.39%
Open: $121.50
Previous Close: $123.44
52 Week Range: $58.53 - $131.82
Oustanding Shares: 417,122,477
Market Cap: 51,514,625,910
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 19 21 21 21
Moderate Buy 2 2 2 2
Hold 4 3 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.40 1.29 1.35 1.35
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 02/27/06
Price Earnings Ratio: 37.54
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
37.54 37.50 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
24.21% 77.82% 119.95%
GROWTH 12 Mo 3 Yr CAGR
Revenue 13.70 1.05 0.27
Net Income 10.50 0.87 0.23
EPS 15.80 1.00 0.26
Earnings for CELG:
EBITDA 2.20B
Revenue 5.51B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $1.31 $1.29 $5.34 $6.50
Number of Analysts 4 4 4 4
High Estimate $1.36 $1.37 $5.59 $7.09
Low Estimate $1.25 $1.26 $5.14 $6.15
Prior Year $1.12 $1.19 $4.50 $5.34
Growth Rate (Year over Year) 16.74% 8.61% 18.61% 21.73%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Stock_Alerts
Stock_Alerts: What is up with these stocks $EMC $HEPI $BIDU $AAPL $IAUS $CPTC $NHPR $ACCR $ARMH $CELG $SDGL $MO $MSFT $CSCO http://t.co/VBLsa4Xm3W
1 hour ago from web
getbillasap
getbillasap: still long weekly $celg 120 calls at 3.90.
1 hour ago from web
getbillasap
getbillasap: closed $celg shares at 124.98 from 123.90. I'm a little confuse because day high is showing 124.97...
1 hour ago from web
kevmcgreevy
kevmcgreevy: @getbillasap ya, I got lucky for sure with the timing, limit order filled on yesterday's spike, re-bought this am $celg
1 hour ago from Echofon
BioWireFeed
BioWireFeed: Investing in Cancer Research Is Worth the Risk: Echo He http://t.co/peakKyr7zX $AMGN $CELG $CLVS $GALE $INFI $RHHBY $THLD
2 hours ago from Tweet Button
AndyLewis5
AndyLewis5: Long $CELG JUNE 125 calls @4.20 with 3 stop. Biotechs resiliant
2 hours ago from web
JBoorman
JBoorman: What positions are working well for u today? I have the following in long-term uptrends and up today: $TWX $HTZ $ASGN $S $CERN $PKG $CELG
3 hours ago from StockTwits Web
DownsideHedge
DownsideHedge: $CELG Twitter sentiment confirming the uptrend, but not showing strong accumulation near 50 dma. http://t.co/CYeH10F1bf
4 hours ago from StockTwits Web
FVPetro
FVPetro: Such a good biotech play. $CELG http://t.co/yhdzVV19ya
4 hours ago from Twitter for iPad
kevmcgreevy
kevmcgreevy: @chasingthealpha remember when talk was $celg would be bought for 105, seems like a long time ago, was only like 6-8 months ago
4 hours ago from Echofon

bullishCelgene numbers raised at Jefferies

Jul 27, 2012 | 8:10 AM EDT

Shares of CELG now seen reaching $80, Jefferies said. Estimates also raised on strong earnings. Buy rating.

bearishCelgene upgraded at Argus

Jun 29, 2012 | 8:37 AM EDT

CELG was upgraded from Hold to Buy, Argus Research said. $75 price target. Stock appears oversold, following a 20% decline.

 

Argus upgrades CELG to Buy from Hold and sets target price at $75 saying the shares have fallen more than 20% from their 52-week on April 3, most recently on a negative pipeline announcement for Revlimid. However, they do not expect this setback to have a 20% impact on earnings.

Read more: http://www.briefing.com/InPlayEq/InPlay/InPlay.htm#ixzz1zBXuxLp3

Looking for a Dollar Comeback

By

Carolyn Boroden

 | Jun 22, 2012 | 9:30 AM EDT

Keep an eye on the greenback, as it may soon resume its longer-term rally.

bearishCelgene numbers lowered at Jefferies

Jun 22, 2012 | 8:28 AM EDT

Shares of CELG now seen reaching $75, Jefferies said. Estimates also lowered on approval delay. Buy rating.

bearishCelgene estimates, target cut at Morgan Stanley

Jun 22, 2012 | 8:09 AM EDT

Shares of CELG now seen reaching $75, according to Morgan Stanley. Estimates also reduced, given disappointing trial data for Revlimid. Overweight rating. 

Celgene Not Done and Dusted

By

Jim Cramer

 | Jun 21, 2012 | 11:45 AM EDT

It is now imperative that Celgene show growth away from Revlimid.

A Celgene Setup Is Bubbling

By

Carolyn Boroden

 | Jun 8, 2012 | 10:30 AM EDT

If you're a risk-taker, you may want to pick this up on a trigger.

Taking Full Advantage of Spooked Investors

By

Jonathan Moreland

 | May 1, 2012 | 7:00 AM EDT

Celgene’s shares have dropped since a disappointing report, but this growth story is far from broken.

Separating the Bargains From the Busts

By

Jim Cramer

 | Apr 27, 2012 | 11:14 AM EDT

Declines can be opportunities, but not all declines are opportunities.

bearishCelgene numbers lowered at UBS

Apr 27, 2012 | 7:27 AM EDT

Shares of CELG now seen reaching $85, UBS said.  Estimates also lowered to reflect pricing and collection headwinds.  Buy rating.

Columnist Conversation / Market Updates

Google Faces More Antitrst Probes
By

Doug Kass

 | May 23, 2013 | 4:00 PM EDT
Google faces new antitrust probe over display ad market

Market on Close Imbalance on the Sell Side
By

Doug Kass

 | May 23, 2013 | 3:47 PM EDT
There is about $550 million to sell on the close.
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.